by | Nov 13, 2022 | Uncategorized
Source: Cure Today articles Aphexda was well tolerated and helped the majority of patients collect enough cells to go to transplant, study results showed. Read More
by | Nov 8, 2022 | Uncategorized
Source: Cure Today articles Blenrep did not meet its progression-free survival endpoint in a phase 3 clinical trial for patients with relapsed or refractory multiple myeloma. Read More
by | Nov 8, 2022 | Uncategorized
Salvage therapies appeared to maintain clinical activity among patients with relapsed/refractory multiple myeloma who relapsed after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, according to study results.The findings, published in...
by | Nov 7, 2022 | Uncategorized
Belantamab mafodotin-blmf failed to extend PFS compared with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma, according to topline data from a confirmatory trial released by the agent’s manufacturer.Belantamab mafodotin-blmf...
by | Nov 4, 2022 | Uncategorized
The FDA granted breakthrough therapy designation to elranatamab for treatment of relapsed or refractory multiple myeloma.Elranatamab (Pfizer) is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. The agent is designed to bind to BCMA — which is...
by | Nov 3, 2022 | Uncategorized
Source: Cure Today articles Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may...
